{
    "clinical_study": {
        "@rank": "69076", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness of TLK286 in treatment of\n      metastatic breast cancer."
        }, 
        "brief_title": "Phase 2 Study of TLK286 in Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic diagnosis of breast cancer\n\n          -  Metastatic disease\n\n          -  Measurable or evaluable disease\n\n          -  No prior chemotherapy regimens\n\n          -  Age at least 18 years\n\n          -  Adequate liver and kidney function\n\n          -  Adequate bone marrow function\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Unstable medical conditions\n\n          -  Chemotherapy within 14 days of TLK286\n\n          -  Radiation therapy within 14 days of TLK286\n\n          -  Hormonal therapy within 14 days of TLK286\n\n          -  Immunotherapy within 14 days of TLK286\n\n          -  CNS metastasis unless controlled by treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "May 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035841", 
            "org_study_id": "TLK286.2008"
        }, 
        "intervention": {
            "intervention_name": "TLK286", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 21, 2011", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Arizona Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Taussig Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase 2 Study of TLK286 in Metastatic Breast Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035841"
        }, 
        "responsible_party": {
            "name_title": "Gail Brown, M.D. Chief Medical Officer", 
            "organization": "Telik, Inc."
        }, 
        "source": "Telik", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Telik", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2011"
    }, 
    "geocoordinates": {
        "Arizona Cancer Center": "32.222 -110.926", 
        "Cleveland Clinic Taussig Cancer Center": "41.499 -81.695", 
        "Indiana University Medical Center": "39.769 -86.158"
    }
}